PLGA nanoparticles for the oral delivery of 5-fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies

Drug Development and Industrial Pharmacy

Volumn 34, Issue 1, 2008, Pages 107-115

  Li, Xueming ^a,b   Xu, Yuanlong ^a   Chen, Guoguang ^a   Wei, Ping ^a   Ping, QiNeng ^b  

^a NANJING TECH UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Drug release; High pressure homogenization; Nanoparticles; PLGA; W O W emulsion

Indexed keywords

AMMONIA; FLUOROURACIL; NANOPARTICLE; POLYGLACTIN; SOLVENT; WATER OIL CREAM;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STRUCTURE; EMULSION; ENCAPSULATION; EVAPORATION; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; RAT; SINGLE DRUG DOSE; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; EMULSIONS; FLUOROURACIL; HALF-LIFE; LACTIC ACID; MALE; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 38549117219     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701484593     Document Type: Article

References (21)

1. Arbos, P., Campanero, M. A., & Irache, J. M. (2002). RP-LC determination of 5-fluorouridine in nanoparticulate formulations. J. Pharm. Biomed. Anal., 28, 857-866.
2. Avgoustakis, K. (2004). Pegylated poly(lactide) and poly(lactide-co- glycolide) nanoparticles: Preparation, properties, and possible applications in drug delivery. Curr. Drug Deliv., 1, 321-333.
3. Bala, I., Bhardwaj, V., & Hariharan, S., et al. (2006). Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxis system for oral administration. J. Drug Target, 14, 27-34.
4. Bilati, U., Allemann, E., & Doelker, E. (2005). Poly(D,L-lactide-co- glycolide) protein-loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced encapsulation efficiency. J Microencapsul., 22, 205-214.
5. Bodmeier, R., & McGinity, J. W. (1988). Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation method. III. Morphology of the microspheres during dissolution studies. J Microencapsul., 5, 325-330.
6. Budhian, A., Siegel, S. J., & Winey, K. I. (2005). Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J. Microencapsul., 22, 773-785.
7. Chong, C. S., Cao, M., Wong, W. W. et al. (2005). Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Contr. Release, 102, 85-99.
8. Dong, Y., & Feng, S. S. (2005). Poly(d,l-lactide-co-glycolide)/ montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 6068-6076.
9. Govender, T., Stolnik, S., Garnett et al. (1999). PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J. Contr. Release, 57, 171-185.
10. Gutierro, I., Hernandez, R. M., Igartua, M. et al. (2002). Size dependent immune response after subcutaneous, oral, and intranasal administration of BSA loaded nanospheres. Vaccine 21, 67-77.
11. Hariharan, S., Bhardwaj, V., Bala, I., Sitterberg, J., Bakowsky, U., & Ravi Kumar, M. N. (2006). Design of estradiol loaded PLGA nanoparticulate formulations: A potential oral delivery system for hormone therapy. Pharm Res., 23, 184-195.
12. Konan, Y. N., Cerny, R., Favet, J. et al. (2003). Preparation and characterization of sterile sub-200 nm meso-tetra(4-hydroxylphenyl)porphyrin- loaded nanoparticles for photodynamic therapy. Eur. J. Pharm. Biopharm., 55, 115-124.
13. Lamprecht, A., Ubrich, N., Yamamoto, H. et al. (2001). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Expt. Ther., 299, 775-781.
14. Blanco, M. D., & Alonso, M. J. (1997). Development and characterization of protein-loaded poly (lactide-co-glycolide) nanospheres. Eur. J. Pharm. Biopharm., 43, 287-294.
15. Peng, T., Cheng, S. X., & Zhuo, R. X. (2006). Synthesis and characterization of poly-alpha, beta-N-(2-hydroxyethyl) -L-aspartamide-g-poly(L- lactide) biodegradable copolymers as drug carriers. J. Biomed. Mater. Res. A., 76, 163-173.
16. Quintanar-Guerrero, D., Ganem-Quintanar, A., Allemann, E. et al. (1998). Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D,L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. J. Microencapsul., 15, 107-119.
17. McClean, S., Prosser, E., Meehan, E. et al. (1998). Binding and uptake of biodegradable polydl-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci., 6, 153-163.
18. Schachter, D. M., & Kohn, J. (2002). A synthetic polymer matrix for the delayed or pulsatlie release of water-soluble peptides. J Contr. Release, 78, 143-153.
19. Shakweh, M., Besnard, M., Nicolas, V. et al. (2005). Poly (lactide-coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm., 61, 1-13.
20. Shakweh, M., Besnard, M., Nicolas, V. et al. (2005). Poly(lactide- coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm., 61, 1-13.
21. Singh, J., Pandit, S., Bramwell, V. W., & Alpar, H. O. (2006). Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38, 96-105.